Abstract Library

#4524 SIRT7 drives the radioresistance of pancreatic neuroendocrine tumours via the DNMT1-MEN1 axis

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are a rare and highly heterogeneous type of tumour in the pancreas. After failure of standard treatment, patients have poor prognoses. Radiotherapy may be a potential therapeutic modality for such patients. However, PanNETs usually exhibit a radiation “cold” tumour through unclarified mechanisms.

Conference:

Presenting Author: Jianyun J

Authors: Jiang J, Xu J, Liang Y, Chen L, Ji S,

Keywords: pancreatic neuroendocrine tumour, radio resistance, SIRT7, MEN1,

#4332 Efficacy of SIRT radioembolisation of liver metastases of neuroendocrine tumours (NETs): A single institution experience

Introduction: Majority of NET patients develop liver metastases (NET-LM). Improved treatment of NET-LM may prolong survival. In case of liver-dominant metastatic disease, local radionuclide treatment using microspheres could be considered.

Conference:

Presenting Author: Kropinska A

Authors: Kropinska A, Gola M, Sygula A, Hamm M, Ledwon A,

Keywords: SIRT, radioembolisation, neuroendocrine tumour, liver metastasis,

#3998 Selective internal radiation therapy for neuroendocrine liver metastases: Efficacy, safety and prognostic factors – A retrospective single institution study

Introduction: Selective internal radiation therapy (SIRT) has shown good results in unresectable liver metastases from neuroendocrine neoplasms (NENLMs) with a high disease control rate (DCR) reported (Braat et al., 2019).

Conference:

Presenting Author: Borbath I

Authors: Briol D, Cerrati A, Annet L, Danse E,

Keywords: SIRT, liver metastases, Prognostic factor, safety,

#3932 Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,

#3875 Investigation on dose-toxicity and dose-response relationship in neuroendocrine liver metastases treated with Holmium-166 radioembolization

Introduction: Radioembolization is a viable treatment option for neuroendocrine liver metastases.

Conference:

Presenting Author: Ramdhani K

Authors: Ramdhani K, Verduin J, Smits M, Bruijnen R, Lam M,

Keywords: Radioembolization, SIRT, holmium-166, neuroendocrine liver metastasis,